Asia Value & Moat Stocks is a research service for value investors seeking Asia-listed stocks with a huge gap between price and intrinsic value, leaning towards deep value balance sheet bargains (i.e., buying assets at a discount e.g., net cash stocks, net-nets, low P/B stocks, sum-of-the-parts discounts) and wide moat stocks (i.e., buying earnings power at a discount in great companies like "Magic Formula" stocks, high-quality businesses, hidden champions and wide moat compounders). Sign up here to get sta ...

Core Viewpoint - Advanced Micro Devices (AMD) is experiencing renewed upward momentum in pre-market trading, driven by a reassessment of the semiconductor sector following Nvidia's earnings report, despite a recent sharp decline in its stock price [1][2]. Stock Performance - AMD closed at $223.55 per share, reflecting an 11.27% drop over the past five trading days, but rebounded to $232.80 in pre-market trading, gaining 4.14% [2]. - The median consensus price target for AMD stands at approximately $258, indicating a potential double-digit upside from current pre-market levels [8]. Market Sentiment - The shift in sentiment towards AMD was influenced by Nvidia's better-than-expected third-quarter results, which alleviated concerns regarding a slowdown in AI-related spending [4][5]. - Investor confidence is primarily driven by reassurances that AI spending remains on track, rather than significant changes in AMD's fundamentals [9]. Analyst Insights - Analysts from Morgan Stanley and Jefferies have described AMD as undervalued relative to its AI peers, with price targets of $260 and $270 respectively [7]. - Institutional analysts suggest that AMD is gaining market share as data center operators seek hardware diversification, particularly for energy-intensive AI workloads [6]. Industry Outlook - Nvidia's strong data center guidance for Q4 signals robust AI investment, which is seen as a positive indicator for AMD and other companies in the sector [5]. - As long as data center operators prioritize GPU and CPU hardware upgrades into 2026, AMD is likely to remain a key strategic beneficiary [10].

Company Overview - Cytek Biosciences (CTKB) is a biotechnology company specializing in cell analysis through its Full Spectrum Profiling (FSP) spectral cytometry technology, which captures the full emission spectrum of each fluorochrome, resulting in higher-parameter and more detailed analysis of cells [1]. Technology and Innovation - The FSP technology allows for enhanced cell profiling, which is crucial for various applications in research and clinical settings, potentially leading to improved diagnostics and therapeutic strategies [1].

Core Insights - The article discusses the expertise of Vladimir Dimitrov, CFA, who has a background in brand and intangible assets valuation, particularly in the technology, telecom, and banking sectors [1]. Group 1: Analyst Background - Vladimir Dimitrov has worked with some of the largest global brands in various sectors, indicating a strong professional network and experience [1]. - He graduated from the London School of Economics, which adds credibility to his analytical skills and knowledge base [1]. - The focus is on identifying reasonably priced businesses that possess sustainable long-term competitive advantages, highlighting a strategic investment approach [1].

Core Viewpoint - TKO Holdings aims to capitalize on the demand for expensive real-life experiences rather than offering virtual experiences for free [1] Group 1 - TKO Holdings is focusing on monetizing real-life experiences, indicating a strategic shift towards premium offerings in the experience economy [1] - The company believes that consumers are willing to pay a premium for authentic, in-person experiences, contrasting with the growing trend of free virtual experiences [1] - This approach aligns with broader industry trends where experiential spending is on the rise, suggesting potential growth opportunities for TKO Holdings [1]

Core Insights - Investing in the US dollar-denominated high-yield bond sector can be easily achieved through the State Street SPDR Portfolio High Yield Bond ETF (SPHY) [1] Group 1 - The SPDR Portfolio High Yield Bond ETF (SPHY) is highlighted as a straightforward investment option for gaining exposure to high-yield bonds [1]

Core Viewpoint - The chip maker anticipates strong demand continuing through next year, while recent selloff has made the $4.5 trillion company appear undervalued [1] Company Summary - The company is currently valued at $4.5 trillion, indicating significant market capitalization [1] - Recent market conditions have led to a selloff, contributing to the perception of the company being cheap [1] Industry Summary - The overall demand for chips is projected to remain robust into the next year, suggesting positive industry trends [1]

Core Points - Bright Scholar Education Holdings Limited has set November 18, 2025, as the record date for the dissemination of the Rule 13e-3 Transaction Statement in connection with a "going private" transaction under a Merger Agreement with Excellence Education Investment Limited and Bright Education Mergersub Limited [1][4] - The merger is expected to close in 2025, resulting in Bright Scholar becoming a privately held company, with its American depositary shares (ADSs) no longer listed on the New York Stock Exchange [4] Summary by Sections Merger Agreement - The Company entered into a Merger Agreement on October 13, 2025, with Excellence Education Investment Limited and its wholly owned subsidiary [1] - Record holders of Class A and Class B ordinary shares will receive a copy of the Schedule 13E-3 and the final form of the Plan of Merger [2] Dissent Rights - Record holders wishing to exercise their dissent rights must provide written objections within seven days of receiving the Plan of Merger [3] Company Overview - Bright Scholar is a premier global education service group that provides quality international education to students, equipping them with essential academic foundations and skillsets for higher education [5]

Company Overview - Hofseth BioCare ASA (HBC) is a Norwegian consumer and pet health company focused on sustainability and optimal utilization of natural resources [1] - The company upcycles by converting side streams of the salmon industry into health-improving ingredients for humans and pets [1] Product Offerings - HBC's key products include ProGo®, a mix of bioactive peptides and collagen, OmeGo®, a whole salmon oil, and CalGo® / NT-II® salmon bone powder [2] - ProGo® enhances iron metabolism, leading to increased energy and vitality [3] - OmeGo® provides immune health benefits and aids recovery from viral infections [3] - CalGo® supports bone and joint health, promoting healthy aging and active lifestyles [3] Scientific Research and Development - HBC emphasizes scientific evidence, resulting in academic partnerships and unique health benefit discoveries [3] - The company has secured patents for its findings and has identified potential therapeutics, leading to the establishment of HBC Immunology (HBCI) [3] - HBCI has raised external finance for its lead program targeting prostate cancer and ovarian cancer, along with a molecule aimed at asthma treatment [3] Corporate Structure and Location - HBC is headquartered in Ålesund, Norway, with branches in Oslo, London, Zürich, and Palo Alto [4] - The company is listed on the Oslo Stock Exchange under the ticker "HBC" [4]

Core Insights - Hofseth BioCare ASA (HBC) held an Extraordinary General Meeting on November 20, 2025, where all proposals were approved as per the notice issued on October 30, 2025 [1] Company Overview - HBC is a Norwegian consumer and pet health company focused on sustainability, optimal utilization of natural resources, and full traceability [1] - The company upcycles byproducts from the salmon industry, converting waste into health-improving ingredients for humans and pets [1] Product Offerings - Key products include ProGo®, a mix of bioactive peptides and collagen; OmeGo®, a whole salmon oil; and CalGo® / NT-II®, a salmon bone powder for bone and joint health [2] - ProGo® enhances iron metabolism, leading to increased energy and vitality, while OmeGo® supports immune health and recovery from viral infections [3] - CalGo® promotes bone and joint health, aiding healthy aging and active lifestyles [3] Scientific and Academic Partnerships - HBC emphasizes scientific evidence, resulting in academic partnerships and the identification of unique health benefits [3] - The company has secured patents for its discoveries and has spun out a biotech-focused entity, HBC Immunology (HBCI), which is developing therapeutics for prostate and ovarian cancer, as well as an oral therapy for asthma [3] Corporate Structure - HBC is headquartered in Ålesund, Norway, with branches in Oslo, London, Zürich, and Palo Alto [4] - The company is listed on the Oslo Stock Exchange under the ticker "HBC" [4]